The Arora Report

Rss Facebook Twitter Linkedin

Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

A NEW PROTECTIVE STOP FOR MEAD JOHNSON $MJN

January 12, 2017

This post was just published on ZYX Buy Change Alert.  Profits have been taken on all but 10% of the position.  Consider raising stops on the remaining in the zone of $69.23 to $69.38.  There is still a buyout potential and that is the reason to hold the remaining small quantity with a tight stop. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here to take advantage of a FREE  30 day trial. Check out our enviable performance in both bull and bear markets.

Read More »

WHAT PHARMA INVESTORS OUGHT TO DO AFTER DONALD TRUMP FIRES A SALVO $LABD $PFE $JNJ $MRK $BMY $LLY $PJP $IHE $PPH $IBB $XHI $BBH $BIS

January 11, 2017

Donald Trump knocked yet another industry in his press conference Wednesday, but this time it wasn’t manufacturers or car makers. It was health care. And shares of U.S. pharmaceutical companies promptly fell, dropping by an average range of about 3% to 5%. “We’ve got to get our drug industry back,” he said. “Our drug industry has been disastrous. They’re leaving left and right. They supply our drugs, but they don’t make them here, to a large extent. And the other thing we have to do is create new bidding procedures for the drug industry because they’re getting away with murder.

Read More »

INITIATE OR ADD TO BIOTECH BEAR ETF LABD BASED ON TRUMP COMMENT $LABD $IBB $XBI $PJP $PPH $XPH $IHE $BMY $MRK

January 11, 2017

This post was published on ZYX Buy Change Alert. Initiate or add in the zone of $13.50 to $14.52. Suitable only for aggressive investors More later as it is moving fast.   COMMENT $LABD $IBB $XBI $PJP $PPH $XPH $IHE $BMY $MRK As a full disclosure, paying subscribers to ZYX Buy Change Alert recently took profits on LABD when it went over $19 and then were given another call to buy LABD again on pullback.  These calls were in addition to the post reproduced above. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A

Read More »

REDUCE MYLAN ON TRUMP COMMENT $MYL

January 11, 2017

This post was published on ZYX Buy Change Alert.  Consider reducing MYL position to 30% of the full core position size if holding a larger position. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here to take advantage of a FREE  30 day trial. Check out our enviable performance in both bull and bear markets.

Read More »

FIVE UNPOPULAR, BUT PRUDENT, THINGS FOR INVESTORS TO DO NEAR DOW 20,000 $MLM $GIS $NVDA $SPY $AAPL $URI $MRK $JNJ $BMY $LLY $AVGO $INTC $ORCL

January 10, 2017

  I can safely say that, from my 35 years in the financial markets, to be consistently successful at investing, one must put prudence over popularity. Human nature as it is, investors often find it difficult to take unpopular actions. My motivation in writing this column is to nudge you to take five unpopular, but prudent, actions today. But before I do that, let’s look at two charts and understand the concept of “over-owned.” Two charts The charts compare five currently over-owned stocks in five sectors of the S&P 500 Index SPX,  The first is a daily chart of the

Read More »

INTELLIGENCE: SEVEN POTENTIAL BIOTECH BUYOUT TARGETS IN WAKE OF ARIAD BUYOUT $ARIA $BMRN $EXEL $FOLD $INCY $MDVN $RARE $SGEN $TSRO

January 9, 2017

This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide intelligence on trades that we do not recommend, but our subscribers may be able to take advantage. Previously our subscribers benefited handsomely from buyout of MDVN.  MDVN was long from $55.50 and the stock was tendered at $81.50 producing an annualized return of 149%.  In the wake of MDVN buyout, we published a

Read More »

OUR POSITION ARIAD PHARMA GETS $24 BUYOUT OFFER, 237% RETURN FOR OUR SUBSCRIBERS $ARIA $ALIOY $TKPYY

January 9, 2017

This post was published on ZYX Buy Change Alert.  Original ARIA position is long from $7.11.  The buyout price represents 237% return.  If you bought subsequently you are long from about $8.80.  ARIA has accepted a $24 per share cash buyout offer from Takeda (TKPYY). We had expected the 118th company in our portfolio to receive a buyout offer or benefit significantly from M&A to be ALIOY, but it turned out to be ARIA.  ALIOY is still in play and if it receives an offer it will be the 119th company. What To Do Now Those holding ARIA may consider tendering their shares for

Read More »

WEEKLY MARKET DIGEST: CHINA AND MEXICO ACT OUT OF FEAR OF TRUMP, WAGES RISE MOST SINCE 2009 $DIA $GLD $QQQ $SLV $SPY $TBF $TBT $USO

January 6, 2017

   Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report.  Please scroll down for the section What To Do Now. WAGES RISE MOST SINCE 2009, BOTH LONG AND SHORT-TERM OPPORTUNITIES AHEAD FROM THE EARNINGS SEASON January 6, 2017 This is what you need to know

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content